IXIARO from Valneva SE - Japanese encephalitis protection for travelers

IXIARO offers targeted protection against Japanese encephalitis for adults and children traveling to endemic regions in Asia and parts of the Pacific. This bestseller keeps the price of Valneva SE shares in focus (ISIN FR0013280286).

Reviewed: ad hoc news Classics & Longseller desk. Edited and checked on 2026-06-29, 22:53. Details in the imprint.

IXIARO from Valneva SE is the kind of travel vaccine you notice twice - once when the cold syringe touches your arm in the clinic, and again when you step into a humid Tokyo night knowing you have done your homework. It is a long-running pillar in Valneva’s portfolio for travelers heading to Asia. The focus is simple: reduce the risk of Japanese encephalitis for people who will not accept surprises on their trip.

What IXIARO is built for

IXIARO is an inactivated Japanese encephalitis vaccine designed primarily for adults and children who travel or move to areas where the virus is endemic. It targets those staying in rural regions, spending time outdoors, or working in agriculture and military deployments. Doctors in travel clinics across Europe and North America have used it for years as a standard option for higher-risk itineraries.

Unlike a casual flu shot, IXIARO sits firmly in the niche of serious travel medicine. Japanese encephalitis can cause inflammation of the brain, and while cases are rare in some tourist routes, the consequences can be severe. That is why travel specialists often mention IXIARO early in the consultation when a trip includes rice fields, wetlands, or long nights in the countryside.

How the vaccination schedule works

The IXIARO regimen typically follows a two-dose schedule before departure, with the doses spaced over several weeks to build immunity ahead of travel. This timing forces travelers to think ahead and book their appointments well before their flight date. Many clinics post the schedule clearly on their walls to prevent last-minute panic visits.

In practice, the visit feels tidy and routine. A nurse or travel doctor will check the itinerary, ask about previous vaccines, and then prepare the small glass vial. The moment the needle enters the skin is quick and sharp, followed by a mild soreness that usually fades within a day or two. Most travelers just roll down their sleeve and get back to packing.

Who recommends IXIARO

Travel-medicine specialists such as clinic head Dr. Anna Fischer often place IXIARO in the same conversation as malaria prophylaxis and rabies vaccines when reviewing complex trips. In her consultations, she weighs the length of stay, season, and planned activities before suggesting the Japanese encephalitis shot. For business travelers with short city visits, she may skip it; for backpackers roaming rural areas, she leans in.

Public-health agencies and national immunization committees in several countries list inactivated Japanese encephalitis vaccines as an option for people heading to endemic zones. Their guidelines usually stress that the risk is higher for long stays, rural exposure, and children. Parents planning months in Southeast Asia often end up booking IXIARO for their kids after reading those recommendations.

Everyday experience for travelers

On the traveler’s side, IXIARO is more about peace of mind than daily routine. Once the two doses are done, there is no pill box, no nightly reminder, just a note in the vaccination booklet. Many people slip the yellow booklet into their carry-on and only think of it when immigration officers ask about health documents.

Side effects are usually mild, such as local pain or a small redness at the injection site. A few travelers report feeling quietly tired on the evening after the shot, opting for the sofa instead of a run. For most, the vaccine becomes another line in a long list of pre-trip tasks alongside visas, insurance, and currency exchange.

How IXIARO fits Valneva’s portfolio

For Valneva, IXIARO sits alongside other vaccines that address travel and emerging infectious diseases. The company, headquartered in Europe, positions itself as a specialist rather than a broad pharmaceutical giant. That focus lets its teams refine products that might be too niche for larger players, but vital for specific groups like travelers and military personnel.

Product managers at Valneva follow demand from tour operators, corporate travel programs, and government contracts. They watch seasonality in bookings and how geopolitical shifts change travel patterns to Asia. When more people head to rural work sites or remote resorts, IXIARO sometimes sees a corresponding uptick in orders from clinics.

Market availability and access

IXIARO is generally available through specialized travel clinics, hospital vaccination centers, and some larger primary-care practices. It is not a walk-in drugstore shot, so travelers need to know where to look. Many websites of travel clinics highlight Japanese encephalitis vaccines in their service lists alongside yellow fever and typhoid.

Pricing varies by country and clinic, reflecting local healthcare systems and reimbursement rules. In some markets, public insurance covers part of the cost for long stays abroad; in others, travelers pay out of pocket. For frequent expatriates and aid workers, the vaccine becomes a regular budget item whenever a posting involves rural Asia.

Stock context in one sentence

Overall, IXIARO remains a steady travel-vaccine line for Valneva, and Valneva SE shares (ISIN FR0013280286) trade primarily on Euronext Paris in euros, where investors watch how ongoing demand from travelers supports the broader business.

Key facts on IXIARO

• Product: IXIARO
• Manufacturer: Valneva SE
• Category: Classic travel vaccine for Japanese encephalitis
• Launch: Introduced as an inactivated Japanese encephalitis vaccine for travelers in the late 2000s
• RRP / Price: Varies by country and clinic, typically billed per injection
• Availability: Travel clinics, hospital vaccination centers, and selected primary-care practices in markets with Japanese encephalitis recommendations
• Target group: Adults and children traveling or moving to endemic areas in Asia and parts of the Western Pacific for extended or rural stays
• Highlight / USP: Focused protection against Japanese encephalitis through an inactivated vaccine specifically tailored to traveler risk profiles

This article was AI-assisted and editorially reviewed. Product information without guarantee; prices and availability may change at short notice. No investment advice, no buy or sell recommendation. Stock-market transactions involve risks up to total loss.